Gene testing in triple negative breast cancer at two points: before and after chemotherapy

Recruiting

Brief Summary: It is expected that 232,832 patients will be diagnosed with breast cancer in India in 2025. Triple-negative breast cancer (TNBC) is a subtype that does not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) andtherefore, such patients do not benefit from hormonal or HER2 directed

therapy.

The current standard of management of patients with TNBC more than 2 cm primary tumor size is neoadjuvant chemotherapy, followed by surgery and subsequently radiotherapy, as indicated. Despite this, around 50% of patients with TNBC will eventually developchemoresistance, recur systemically and succumb to cancer.

The mechanisms of chemoresistance in the residual tumor tissue are not known. To addressthis knowledge gap, we aim to compare the targeted genomic (germline and somatic) profiles of baseline tumor samples with that of post-neoadjuvant chemotherapy surgical specimenfrom a prospective cohort of patients with TNBC.

Recruitment & Eligibility

Inclusion Criteria

Patients diagnosed with triple negative breast cancer Non metastatic disease Planned for neoadjuvant chemotherapy Willing to participate in study.

Exclusion Criteria

Patients with prior history of cancer Patients planned for upfront surgery.

Primary Outcome Measures

Name	Time	Method
Identification of targetable mutations in residual disease in triple negative breast cancer that were not initially present in the tumor cells and in germline	Six months

Secondary Outcome Measures

Name	Time	Method
Identifying the associations between differential mutations with disease-free survival of patients with triple negative breast cancer	Identification of genetic mutations associated with incomplete response to chemotherapy

Locations (1): AIIMS New Delhi
🇮🇳
South, DELHI, India
AIIMS New Delhi
🇮🇳South, DELHI, India
Atul Batra
Principal investigator
01129575043
batraatul85@gmail.com